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ABSTRACT 
MELISSA ANN HOLY: G-quadruplex Mediated Splicing of p53 mRNA 
(Under the direction of Dr. Tracy A. Brooks) 
 
 The protein p53 is a master regulator of the cell cycle and its 
mutation/inactivation is associated with over 50% of cancer cases. Mutations in p53 are 
associated with worse survival rates, resistance to therapies, and other risk factors in 
breast cancer specifically. p53 is encoded by the TP53 gene and is expressed as several 
transcripts. In the G-rich portion of intron 3, secondary DNA structures known as G-
quadruplexes are able to form. The stabilization of these G-quadruplexes leads to correct 
splicing of intron 2, thus making a functional p53 protein. A known quadruplex-
stabilizing compound (TMPyP4) was tested to determine its ability to stabilize these 
structures through electronic circular dichroism. The effect TMPyP4 had on pre-mRNA 
splicing of p53 in MCF-7 breast cancer cells was also evaluated through real-time 
quantitative polymerase chain reaction and gel electrophoresis. This compound did 
possess stabilizing qualities in the intron 3 region of the TP53 gene. Although more 
pharmacologic testing needs to be completed, TMPyP4 shows potential to regulate 
splicing of p53, which could improve the prognosis of breast cancer patients.  
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INTRODUCTION 
 
 The tumor suppressor gene p53 acts as a master regulator of the cell cycle; its 
mutation is responsible for more than 50% of cancer cases (Attardi, 2000). In breast 
cancer specifically, p53 mutations are associated with worse survival rates, resistance to 
anticancer therapies and other risk factors (Miller, 2005). The p53 gene is located on the 
short arm of chromosome 17 at position 13.1 as shown in Figure 1 (TP53 gene, 2015). 
The p53 protein is 393 amino acids long and contains five different domains (Berkson, 
2005). Under normal conditions, p53 will respond to stress, such as DNA damage, and 
turn on many different biological pathways to impede the cell cycle, reduce the 
replication of damaged DNA, and facilitate either DNA repair or programmed cell death 
(apoptosis) (Chiu, 2014). 
 The five previously mentioned domains of the p53 protein are evolutionarily 
conserved and serve separate functions (Kumari, 2015). A map of these domains can be 
seen in Figure 2. The first of these domains is the N-terminal acidic domain, which is 
responsible for the transactivation function of p53 (Berkson, 2005). This domain is able 
to accomplish transactivation by interacting with basal transcriptional machinery, such as 
the TATA-binding protein (TBP) (Kumari, 2015). The second of these domains is the 
proline-rich domain, containing five repeats of PXXP (where P designates a proline and 
X could be any other amino acid) (Walker, 1996). Adjacent to the proline-rich domain is 
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Figure 1 location of the p53 gene on chromosome 17 
From Berkson, R. G., Hollick, J. J., Westwood, N. J., Woods, J. A., Lane, D. P., & Lain, 
S. (2005, February 23). About p53. http://ghr.nlm.nih.gov/gene/TP53. 
 
 
 
 
Figure 2 domain organization of the p53 protein 
From Kumari, R., Sen, N., & Das, S. (2014). Tumor suppressor p53: Understanding the 
molecular mechanism inherent to cancer. Current Science, 107(5), 786-794. 
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the one most pertinent to p53 related cancer research, as 97% of tumor-associated 
mutations occur in this domain. In addition, many carcinogens seem to be attracted
to this domain due to the growth advantage caused by mutations it can offer the cells 
(Sigal, 2000). This DNA-binding domain is the central part of the protein and contains a 
sequence-specific DNA-binding domain, spanning residues 102-292, that binds to the 
consensus sequence (Harms, 2006). The forth domain is the oligomerization domain, 
which serves to tetramerize p53 into its functional state (Kumari, 2015). The final 
domain, consisting of the last 30 amino acids, is the C-terminal domain (Berkson, 2005). 
This domain has been found to regulate p53 function due to its ability to influence 
activity under stress conditions (Kumari, 2015). This is accomplished because nearly 
every amino acid contained in this domain is able to undergo posttranslational 
modifications (Harms, 2006). 
The functional p53 protein is able to respond to a multitude of signals including 
DNA damage, irregular oncogenic events, hypoxia, and starvation. Loss of DNA 
integrity can occur by gamma irradiation, UV irradiation, oxidative free radicals, and 
many other intrinsic and extrinsic pathways (TP53 gene, 2015). These agents can cause 
modifications in the DNA such as incorrect base pairing, deletions, mutations, and 
chromosomal aberrations. Multiple changes in the DNA can result in altered gene 
function, most likely a loss of function for tumor suppressor genes and enhanced activity 
for oncogenes. The way these factors affect p53 specifically is by triggering many 
sensory serine/threonine kinases that play important roles in its activation (Kumari, 
2015). Oncogenes are able to activate p53 through the damaged DNA response or 
through the transcriptional activation of p14ARF (Scott, 1998). Under normal conditions, 
 4 
p14ARF is able to stabilize p53 and allow it to respond to oncogenic events. It has been 
found that decreased expression of p14ARF is a common feature in many human  tumors 
(Scott, 1998). Other signals that activate p53 include the absence of nutrients, energy, or 
oxygen. Reduced oxygen or nutrient levels activate AMPK, which in turn stabilizes p53 
directly through phosphorylation. Stabilizing p53 ensures it is able to moderate the cell 
cycle (Scott, 1998). 
The activation of p53 has a variety of downstream effects on the cell, which 
include cell-cycle arrest, senescence, apoptosis, DNA repair, reshaping metabolism, and 
activation of miRNAs. Typically, p53 acts as a transcription factor with the potential to 
induce expression in many different genes. For p53 to effectively induce cell-cycle arrest, 
it is dependent on one of three genes: p21, 14-3-3σ or GADD45a (Kumari, 2015). p21 
was the first transcriptional target of p53 to be identified. It has the ability to arrest the 
cell in the G1 phase through the inactivation of three separate cyclin/CDK pairs (El-
Deiry, 1993). Arrest in the G2 phase is primarily dictated by the activation of both 
GADD45a and 14-3-3σ. GADD45a is silenced in breast and prostate cancers though 
hypermethylation (Jin, 2002). 14-3-3σ serves to inhibit transport of cyclin B1 and CDC2 
into the nucleus (Kumari, 2015). Silencing of 14-3-3σ is a significant factor leading to 
breast cancer. The second activity p53 is responsible for activating is senescence, which 
is the arrest of cell growth followed by characteristic changes in the phenotype of the cell 
(Chiu, 2014). While this method of inactivation is well established, the mechanisms are 
poorly understood.  
The third mechanism p53 is able to initiate is apoptosis (Chiu, 2014). Because this 
mechanism is irreversible, it is typically performed on irreparably damaged cells or in 
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response to sustained stress conditions. p53 has the ability to activate Bax, Noxa and
PUMA genes that subsequently allow the release of cytochrome c from the mitochondria 
into the cytoplasm. In addition, p53 contributes to the apoptosome formation through 
transcriptional activation of APAF-1 (Kumari, 2015). Extrinsically, p53 also has a 
function. It is responsible for transcriptional activation of KILLER/DR5 and Fas. PERP 
and PIDD are also key components in p53-mediated apoptosis and loss of their 
expression decreases the effectiveness of p53-mediated apoptosis (Attardi, 2000).  
The gene regulator, p53 is also responsible for stopping propagation of deleterious 
mutations in DNA. The effect p53 can have on damaged DNA is seen through both the 
expression of repair proteins and interactions with the repair machinery. p53 is 
responsible for activating a multitude of genes involved in DNA repair, such as MLH1 
and PMS2 in mismatch repair and DDB2 in nucleotide-excision repair (Kumari, 2015).  
Reshaping various aspects of cell metabolism, a newly discovered function, 
allows p53 to regulate rates of proliferation in tumor cells. In particular, p53 is able to 
regulate glycolysis by repressing GLUT1/4, PGM, TIGAR, and SOC2 genes (Kumari, 
2015). By repressing the expression of GLUT 1 and GLUT 4, p53 is able to limit glucose 
transport into the cell (Schwartzenberg-Bar-Yoseph, 2004). Uncharacteristic expression 
of PGM increases glycolysis rates and can lead to unregulated proliferation and resistance 
to oncogene related senescence. TIGAR, also activated by p53, can suppress glycolysis; 
while, SOC2 enhances TCA cycle for energy (Bensaad, 2006). Taken together, p53 
functions to decrease glucose utilization and a loss of p53 function shifts the cell towards 
glycolysis.  
By transcriptionally activating anti-oxidant factors, p53 is responsible for the 
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degradation of reactive oxygen species, a byproduct of normal metabolism (Hu, 2010). 
The final outcome p53 is responsible for is the induction of microRNAs (miRNAs)
These are RNAs are non-coding sequences, in that they do not produce functional 
proteins, 20-24 nucleotides long, and they are important in post-transcriptional regulation 
of gene expression (Hu, 2010). These miRNAs play roles in cell cycle, cell survival, and 
metabolism; thereby, they have an effect on tumor suppression and stress responses (Hu, 
2010). 
 The regulation of p53 is a complex process moderated by many proteins that can 
modify it for stabilization, reverse these modifications, and regulate translation of p53 
mRNA. Under non-damaged cellular conditions, p53 is kept at lower levels so that the 
cell cycle can proceed. The ligase MDM2, which is in the family of E3 ubiquitin ligases, 
is responsible for the regulation of p53 stability. The distortion of its function is a feature 
in many tumors. MDM2 binds to p53 and induces polyubiquitylation that leads to 
proteasomal degradation. MDM2 and p53 are regulated through a negative feedback 
loop: p53 induces MDM2 expression while MDM2 inhibits p53, each contributing to the 
expression of function of the other.  Elevated levels of MDM2 leads to decreased levels 
of p53, and have been detected in many cancers including 31% of breast carcinomas. The 
high levels of MDM2 can be attributed to many causes, such as gene amplification, 
increased transcription, and improper post-translational modifications. Although 
ubiquitination is the most important mechanism, p53 can also be regulated through post-
translational modifications such as phosphorylation, acetylation and other modifications 
to lysine residues (Kumari, 2015).  
 p53 is encoded for on the TP53 gene, which consists of 11 exons that are spliced 
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to make 10 different functional and nonfunctional isoforms (Berkson 2005). The fully 
spliced p53 (FSp53) is the wild type protein, which contains 11 exons. It is able to induce 
growth suppression in response to stress in addition to many of the functions previously 
listed. However, alternative splicing can lead to other isoforms, such as Δ40p53, in which 
intron 2 is retained.. It inhibits transcription and interferes with the cell cycle, thus 
causing negative effects on the cell. The Δ40p53 isoform lacks the first 39 N-terminal 
residues, which correlates to the transactivation domain described earlier. Because the 
isoform Δ40p53 maintains intron 2, stop codons are introduced, therefore preventing 
complete synthesis of the protein. Expression of this type occurs in cancer cell lines such 
as MCF-7 (Marcel 2010).  
Stabilization of intron 3 in TP53 mRNA facilitates correct splicing of intron 2, 
forming the functional FSp53. This is mediated, in part, though the stabilization of non-
canonical DNA secondary structures, called G-quadruplexes, in the GC-rich region of 
intron 3 (Marcel 2010). Davies and his research team first reported these structures in 
1962 in their article “Helix Formation by Guanylic Acid” and their importance has since 
been validated (Gellert, 1962). There have been as many 376,000 putative G-quadruplex 
sequencess reported in the human genome, including telomeres, origins of replication in 
ribosomal DNA, mini-satellites, the immunoglobulin, and oncogene promoter regions 
(Ou, 2008). Specifically, promoter regions of oncogenes such as c-MYC, c-Kit, kRAS, 
pRb, Bcl-2, VEGF-A, hTERT and PDGF-A have been shown to form G-quadruplexes 
(Brooks, 2010). Hallmarks of cancer, such as insensitivity to anti-growth signals, 
sustained angiogenesis, limitless replicative potential, evasion of apoptosis, self 
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sufficiency of growth signals, and metastasis can arise when the expression of these 
oncogenes is altered (Balasubramanian, 2010). 
G-quadruplex structures form from specific folds in G-rich sequences due to 
superhelical strain, causing relaxation of the DNA double helix, usually due to 
transcription or replication. This relaxation causes disassembly of the double helix and 
enables the formation of a G-quadruplex (Brown, 2013). These structures result from the 
interaction of four guanines in a Hoogsteen hydrogen bond arrangement where each 
guanine nucleotide forms two hydrogen bonds with its neighbor (Marcel 2010). As seen 
in Figure 3, this bonding arrangement makes planar sheets called G-quartets that are able 
to stack on top of each other. When two or more G-quartets stack, the resultant structure 
is a G-quadruplex and is held together by loops exterior to the core (Duchler, 2012). The 
loops are significant factors in determining the G-quadruplex diversity because they are 
highly variable based on stoichiometry, strand direction, glycosidic torsion angle and the 
location of their link to the guanine strand. In addition, the polarities of the four strands 
determine whether the G-quadruplex is in parallel, mixed or anti-parallel configuration. 
The hole made inside the four guanines is suited to bind with a cation, such as K+ and 
Na+, which are known to stabilize intra and intermolecular structures, respectively (Ou, 
2008). 
The important biological functions of the G-quadruplex, such as transcriptional 
regulation, DNA replication, and genome stability, make them promising targets for drug 
design (Lam, 2013). Many traditional anticancer therapies target duplex DNA; however, 
many of these ligands can be extremely cytotoxic and nonspecific. Ligands are capable of 
three distinct modes of binding to G-quadruplex structures: stacking, intercalating, and 
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groove binding, as seen in Figure 4. Intercalating binding, which occurs when the ligand 
interacts between the stacks of G-tetrads, is the most effective in stabilizing the G-
quadruplex DNA, ex vivo (Ou, 2008).  The problem arises in vitro because the 
intercalating mode is costly and requires disruption of the quadruplex. Thus, it is not the  
Figure 3 schematic representations of G-quadruplex structures  
From Marcel, V., Tran, P. L., Sagne, C., Martel-Planche, G., Vaslin, L., Teulade-Fichou, 
M., …Van Dyck, E. (2010). G-quadruplex structures in TP53 intron 3: Role in alternative 
splicing and in production of p53 mRNA isoforms. Carcinogenesis, 32(3), 271-278. 
 
 
Figure 4 a representation of a ligand bound to a G4 complex with a) external stacking 
mode, b) intercalating mode and c) groove binding mode 
From Ou T, Lu Y, Tan J, Huan Z, Wong K, Gu L. G-quadruplexes: targets in anticancer 
drug design. ChemMedChem. 2008 May 19; 3(5): 690-713. 
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primary mode of binding considered during drug design. G-quadruplexes seem to prefer 
stacking or loop-interactive modes of binding, using either the latter side (groove binding, 
or the surface of the terminal G-quartets (stacking) (Ou, 2008). A structural commonality 
between all G-quadruplexes is the large planar surface of the G-quartet. While this 
feature is unlikely to confer selectivity, it has been a primary design of G-quadruplex-
targeted small molecules (Balasubramanian, 2010). The research of this field has shifted 
away from molecules like this and towards highly specific ligands with decreased non-
specific selection effects (Neidle, 2009). Depending on the size of the molecule, stacking 
compounds may be capable of extending past the tetrad and interact with the loops. 
Because of the variations contained in the loops, the number of tetrads, polarities, and 
cation associations, G-quadruplexes make great targets for anticancer therapies; small 
molecules can preferentially interact with G-quadruplex, over duplex DNA, and 
selectively bind to particular non-canonical structures.  
 The first-in-class G-quadruplex drug, Quarfloxin, is the most successful 
compound, to date, in stabilizing select G-quadruplex structures; it was able to advance to 
Phase II clinical trials before problems in albumin binding prevented the trial from 
continuing (Brown, 2013). Aside from the pharmacokinetic issues, Quarfloxin had many 
preferred drug characteristics of an effective drug, such as low toxicity and good 
tolerance by patients. Objective responses were recorded in Phase I trials in patients with 
carcinoid/neuroendocrine tumors (Bisacchi, 2016). The success by this drug validates the 
future for G-quadruplex-interacting small molecules. Many other G-quadruplex ligands 
have been created as test molecules, which lack drug-like characteristics. Several 
research compounds lack good drug-like characteristics, but their pan-G-quadruplex 
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stabilizing abilities make them good candidates to uncover G-quadruplex structures ex 
vivo and in vitro. These compounds include cationic porphyrin (TMPyP4), acridine 
(BSU6039), polycyclic acridine (RHPS4), and N,N'-bis-[2-(1-piperidino)ethyl]-3,4,9,10-
perylenetetracarboxylic diimide (PIPER) (Ou, 2008). 
The focus of this study was to examine the effect of G-quadruplex structure 
stabilizing compounds to modulate splicing TP53 mRNA around intron 3. In particular, 
we have studied the formation of a G-quadruplex in intron 3, and its stabilization by two 
cationic porphyrins; TMPyP4, and its inactive stereoisomer TMPyP2. TMPyP4 is known 
to bind to duplex DNA, and has the capacity to both stabilize and unfold DNA 
quadruplexes (Morris, 2012). In addition, it has been found to have the desired 
intercalating interactions with G-quadruplex structures; however, its affinity for 
quadruplex structures is only two fold greater than its affinity for duplex DNA, 
classifying it as a low-selective ligand that binds to all nucleic acids. Its activity is 
compared to its positional isomer, TMPyP2, which does not interact with DNA or RNA. 
TMPyP2 serves as a reference molecule (Ou, 2008). Because p53 is mutated in over 50% 
of cancer cases, the correct splicing of the TP53 gene using selective, G-quadruplex 
stabilization compounds could be a novel approach to anticancer therapies. 
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MATERIALS AND METHODS 
 
Oligomers 
Partial sequence of p53 DNA from beginning of intron 3 to end of intron 4:
 AG3T2G3CTG4AC2TG2AG3CTGXCT (where x=6 or x=7) 
I2 primer: ATGGGACTGACTTTCTGCTCT 
E2/E3 primer: CCTATGGAAACTACTTCCTG 
E4/E5 primer: AGGGGACTACGTGCAAGT 
 
 Electronic Circular Dichroism 
To confirm the binding of TMPyP4 and the subsequently stabilized G-
quadruplex, electronic circular dichroism was performed on p53 DNA. First, a potassium 
chloride titration was run. A 300 µL master mix of 5 µM DNA, 50 mM Tris-acetate, 
varying KCl, and ddH2O was made. For the titration, 0, 10, 25, 50, 75, and 100 µM were 
evaluated for their facilitation of G-quadruplex formation in intron 3 of p53. KCl was 
diluted from a 1 mM stock. The mixtures were then heated to 95°C for ten minutes, 
nanodropped hot to obtain an A260 value, and then allowed to slowly cool to room 
temperature. Blanks for each sample, containing identical contents but lacking DNA 
(replaced with ddH2O), were made to correct for background polarization of light. 
Spectra were measured from 225 – 350 nm on an Olis DSM-20 CD machine coupled to a 
Peltier heat block. To test the compounds, 10 µM TMPyP2 or 10 µM TMPyP4 were 
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added to the DNA mixtures (5 µM DNA, 50 mM tris-acetate, 25 mM KCl, and enough 
ddH2O to make 300 µL per spectra). Again, blanks were made to subtract out background 
data. Spectra were measured from 225 – 350 nm on an Olis CD machine coupled to a 
Peltier heat block. TM on these mixtures were determined by collecting spectra from 20 - 
100°C, measured at every 10°C after holding for 1 minute at temperature. Data were then 
converted to a single value decomposition (SVD) in order to calculate TM using the 
nonlinear regression modeling through GraphPad Prism®. 
 
RT-qPCR 
 Real time polymerase chain reaction (RT-qPCR) was performed to determine the 
effect of TMPyP4 on RNA splicing. 4 x 105 MCF-7 breast cancer cells were plated per 
well in a 6-well plate, with DMEM (supplemented with 10% PBS and 1% 
Penicillin/Streptomycin). The cells were then incubated overnight to allow cells to attach. 
The following day, 50 µM or 100 µM of TMPyP2 or TMPyP4 were added to the 
individual wells; after the addition of the compounds the plates were incubated for 48 
hours. 
 Following the “Mammalian Cultured Cells Total RNA Purification” protocol of 
the GeneJET RNA Purification Kit (Life Technologies), the RNA was extracted. Briefly, 
the media was poured off the cell plates, and the cells were washed twice with 250 µL 
PBS to remove any remaining DMEM. To detach the cells from the bottom of the plate, 
the cells were covered and subsequently lysed by 350 µL of Lysis Buffer supplemented 
with 1% BME. The cells were then collected in 1.5 mL tubes and vortexted to ensure 
complete homogenization. Following this, 360 µL of 100% ethanol was added and mixed 
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by pipetting.  
The lysate mixture (up to 700 µL) was transferred to the GeneJET RNA 
Purification Column, which was placed in a collection tube. It was then centrifuged at 
12000 rpm for 1 minute. The flow-through was discarded and the purification column 
was placed in a new collection tube. 700 µL of Wash Buffer, supplemented with ethanol, 
was then added to the top of the purification column, and it was centrifuged at 12000 rpm 
for 1 minute. Again, the flow-through was discarded, and 600 µL Wash Buffer 2, 
supplemented with ethanol, was added to the purification column. The column was 
centrifuged at 12000 rpm for 1 minute. After the flow-through was discarded, 250 µL  
Wash Buffer 2, supplemented with ethanol, was added to the purification column and the 
column was centrifuged at 12000 rpm for 2 minutes. The flow-through was discarded for 
the last time and the collection tube was replaced with a sterile, RNase-free 
microcentrifuge tube. The last step was to add 50 µL of nuclease-free water to the center 
of the purification column and centrifuge at 12000 rpm for 1 minute to allow the RNA to 
flow through. Using a NanoDrop 2000 UV-Vis Spectrophotometer, the concentration of 
mRNA was measured.  
The extracted RNA was then used as a template to make cDNA through reverse 
transcription. Using the “First Strand cDNA Synthesis” protocol of the Maxima H Minus 
First Strand cDNA Synthesis Kit (Life Tchnologies), cDNA was made. First, 500 ng of 
template RNA, 0.25 µM of both oligo (dT)18 primer and a random hexamer primer, 1µL 
of 10 mM dNTP Mix and enough nuclease free water for the total volume to equal 15 µL 
was combined. After centrifugation, 4 µL of 5X RT Buffer and 1 µL of Maxima H Minus 
Enzyme Mix were added, in that order, for a total volume equaling 20 µL. After 
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centrifugation, the samples were incubated for 10 minutes at 25°C, then 15 minutes at 
50°C, and finally 5 minutes at 85°C. 
The cDNA synthesized was then used for qPCR; two mixtures were prepared. 
The first contained 1x PCR mix (EvaGreen) and 0.2 µM of each p53 primers (I2 and E4 
or E2/E3 and E4) (Life Technologies). The second mixture contained 1x of Taq buffer 
(SSo Advanced Mix, BioRad) and 0.2 µM of VIC-labeled GAPDH TaqMan primers 
(BioRad. The mixtures were then aliquoted (with enough water to bring sufficient colume 
to 17.5 µL) into well of a 96-well PCR plate. The PCR plate was then placed in a CFX 
Connect Real-Time PCR Detection System. A two channel, two-step fast amplification 
was run (95°C for 5 minutes followed by 40 repeats of 95°C for 15 seconds and 60°C for 
45 seconds) and expression was calculated by normalizing the concentration of p53 to the 
loading control, GAPDH. This was done by using the equation ΔCS1 = CqFAM - CqVIC. 
Following this, the sample effect was again normalized to the no compound control using 
the equation ΔΔCS1 = CqS1 - Cq control. Finally, the fold change over expression was 
calculated by 2-ΔΔ Cq (Haimes, 2010).  
 
Gel Electrophoresis 
After qPCR was used to amplify the cDNA, gel electrophoresis was run in order 
to visualize the RNA. A 1% agarose gel was made by supersaturating 1 gram of agarose 
in 100 mL of a 1x TAE buffer (40 mM Tris base, 20 mM acetic acid, and 1 mM 
ethylenediaminetetraacetic (EDTA) acid). The samples were electrophoresed for 30 
minutes at 100 V. In addition, a molecular weight ladder was used to visualize the 
different sizes of DNA fragments. 
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RESULTS AND DISCUSSION 
 
Deciphering the G-quadruplex sequence ex vivo 
A critical first step in testing the role of G-quadruplexes in p53 splice variations 
was deciphering the correct DNA sequence. The literature concerning this particular 
stretch in the p53 DNA was not consistent. The discrepancy lay within intron 3 at the 
sequence: AG3T2G3CTG4AC2TG2AG3CTGXCT. In particular, the van Dyck team that 
first described this G-quadruplex cited x=7 guanines, while the Achatz group that 
examined the effect of a polymorphism on G-quadruplex formation cited x=6 (Marcel 
2011, Sagne 2014). While this slight variation does not appear to be notable, slight 
sequence variations can markedly affect G-quadruplex formation. Due to a 
polymorphism at that particular location, determining the correct sequence is difficult, 
although browsing the genome indicates x=6. This structural variation could be 
monumental in future therapeutic efforts, as screening with the incorrect sequence is 
unlikely to yield clinically viable compounds. 
Electronic circular dichroism (ECD) was used to determine asymmetrical 
structure formation. Generally, non-chiral molecules are ECD-inactive; whereas, DNA 
within the G-quadruplexes give distinctive spectral maxima and minima. Thus, G-
quadruplexes will display negative minima around 240 nm. For a parallel G-quadruplex, 
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the positive maxima will between 260 - 265 nm; an anti-parallel G-quadruplex also 
possesses positive maxima at about 290 nm.  
Before running ECD with the compounds, a potassium chloride titration was 
completed for x=6 and x=7 p53 sequences. The interaction between G-quadruplexes and 
KCl is very important due to the quadruplex stabilization by potassium ions (K+). The 
titration ranged from 0 mM to 100 mM, with 0 mM being the control for the titration. 
The purpose of the titration is two-fold: to determine the lowest concentration of KCl 
required to stabilize the G-quadruplex formation and to determine the full range of 
thermal stability. G-quadruplex formation is indicated by spectral shifts towards the 
characteristic maxima and minima of this secondary structure, as described above. If the 
potassium chloride concentration is not high enough, there will be no stabilization of the 
G-quadruplex structure; conversely, if the concentration is too high, the effect of the 
TMPyP4 will be minimal. Physiologically, these structures are forming in equilibrium 
with single- and double-stranded DNA. We are trying to define a potassium chloride 
concentration that fosters equilibrium structures. The titration was run on both DNA 
sequences, where x=6 guanines or when x=7 guanines (Figure 5 and Figure 6, 
respectively). With both sequences, 10 mM KCl sample shifted the spectra, but did not 
possess the characteristic maximas of a G-quadruplex and was non-distinct. KCl 
concentrations of 25 mM and above demonstrate a clear shift to the characteristic 
maxima at 265 or 290 and minima around 240 nm. While the DNA with the 6 guanine 
repeat possesses the characteristic anti-parallel wavelength around 290 nm, this is not the 
case for the DNA with 7 guanine repeats. These different spectra confirm our concern 
that a single nucleotide difference (x=6 or 7) can markedly affect G-quadruplex structure.   
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Figure 5 circular dichroism spectra for KCl titration of p53 DNA containing 6 guanine 
repeats displaying both parallel and anti-parallel G-quadruplex structures 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 circular dichroism spectra for KCl titration of p53 DNA containing 7 guanine 
repeats displaying only parallel G-quadruplex structures 
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We believe that physiologically relevant structure (where x=6) is a mixed parallel and 
antiparallel species as seen in Figure 5. 
After the concentration of KCl (25 mM) was established for optimum stability, 
ECD with TMPyP4 was performed to demonstrate its effects on stabilizing the G-
quadruplex structures. CD was performed on both oligomers, one where x=6 and another 
with x=7. Spectra and TM with TMPYp4 was run as described above. KCl (25 mM) is in 
all of the samples and should be fostering G-quadruplex formation and some stability. 
TMPyP2 should have the same spectra as no compound, whereas TMPyP4 may show 
higher maxima. In Figure 7 with x=6 the expected shift in maxima and minima is not 
evident. TMPyP2 displays higher maxima compared to TMPyP4. In Figure 8 with x=7 it 
is clear TMPyP4 stabilized the G-quadruplex as the maxima and minima match the 
characteristic maxima and minima described earlier.  
Using thermal circular dichroism, the melting temperature (TM) of the DNA was 
measured, which is the temperature at which half of the DNA is present as an 
intramolecular G-quadruplex, and half of the DNA is present in single-stranded form. 
The melting temperature is dependent on the stability of the molecule. If the small 
molecules TmPyP2 and TmPyP4 improve the stability of the G-quadruplex, there should 
be an increase in the melting temperature (TM) of the DNA oligomers. Due to TMPyP2’s 
weak interaction with G-quadruplex DNA, it is hypothesized that no increase in melting 
temperature should occur.  
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Figure 7 circular dichrosim spectra for p53 oligomer containing 6 guanine repeats treated 
with TMPyP2 and TMPyP4 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 circular dichrosim spectra for p53 oligomer containing 7 guanine repeats treated 
with TMPyP2 and TMPyP4 
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As seen in Table 1, the trends for x=6 were exactly as anticipated. There was 
actually a decrease in TM from the control to the presence of TMPyP2. However, there is 
a marked increase in the TM values from control to TMPyP4 (17.7°C). In contrast, x=7 
did not show notable when either TMPyP2 and TMPyP4 were added. 
 
 
Control TMPyP2 TmPyP4 
x=6 68.87 °C -7°C +17.7 °C 
x=7 68.87 °C +5.71 °C +4.13 °C 
 
Table 1 TM values for oligomers where x=6 and x=7 treated with TMPyP2 or TMPyP4 
 
RT-qPCR  
Real-time quantitative polymerase chain reaction (RT-qPCR) was used to validate 
the hypothesis that stabilization of G-quadruplexes within the p53 intron 3 could affect 
splicing of the pre-mRNA. In order to normalize the data, GAPDH, a housekeeping gene, 
was employed and its probe-primer pair was VIC-labeled. GAPDH serves as a control 
due to is low variability within tissues and after treatment, and it is expected to amplify 
during real time quantitative polymerase chain reaction.  
The specific primers used to detect fully spliced cDNA were the forward primer 
E2/E3 and the reverse primer E4/E5, which amplify RNA only if intron 2 was correctly 
removed by splicing, producing mature FSp53. To quantify the Δ40p53 mRNA the 
forward primer I2 and the reverse primer E4/E5 were employed. These two primers 
detected if intron 2 to remained intact. TMPyP4, but not TMPyP2, should stabilize the G-
quadruplex in intron 3 and facilitate the removal of intron 2, producing more FSp53. 
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With all TMPyP2 samples, we had an error with the qPCR machine and were unable to 
determine Cq values. We did however obtain the amplification values (Figure 9). There 
should be a shift of the E2/E3 line to the left or the I2 line to the right as compared to the 
internal GAPDH control and as to the amplification plots n the no treatment control, as 
the concentration of TMPyP4 increases. Figure 9A shows the control amplification. As 
seen in Figure 9B and Figure 9C, there was not much change as compared to GAPDH; 
however, the lines for I2 and E2/E3 shifted towards each other. This shift is not predicted 
as the expression of I2 and E2/E3 should not be affected by TMPyP2. As seen in Figure 
9D and Figure 9E the gap between I2 and E2/E3 widened as the concentration of 
TMPyP4 was increased from 50 µM to 100 µM. The suggested difference in expression 
between 100 µM of TMPyP2 and 100 µM TMPyP4 shows stabilization of G-quadruplex 
structures by TMPyP4 as it produced more fully spliced p53. Figure 10 is another 
representation of the increase in correct splicing seen through the addition of TMPyP4. 
With increasing concentrations of TMPyP4, there is an increase in the splicing of the 
fully spliced mRNA. Although this data shows the right trends, there is much variability 
in the values. 
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Figure 9 (A) PCR run on cDNA with no treatment (B) PCR run on cDNA treated with 
50 µM TMPyP2 (C) PCR run on cDNA treated with 100 µM TMPyP2 (D) PCR run on 
cDNA treated with 50 µM TMPyP4 (E) PCR run on cDNA treated with 100 µM 
TMPyP4 
 
D E 
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Figure 10 results from PCR showing the increase of FSp53 (E2/E3) with the increase in 
TMPyP4 (P4) concentration 
 
Gel Electrophoresis 
The cDNA from the PCR plate was electrophoresed in 1% agarose gel in order to 
visualize the DNA fragments. The cDNA was treated with no compound, 50 µM 
TMPyP2, 100 µM TMPyP2, 50 µM TMPyP4, and 100 µM TMPyP4. If there is an 
increase of expression of cDNA treated with TMPyP4, it could be deduced that TMPyP4 
has the ability to stabilize G-quadruplex structures in intron 3, thus creating the correct 
splicing of intron 2 and a fully functioning p53 protein. As expression increases, so did 
the intensity of the band. As seen in Figure 11, there is an increase in expression of fully 
spliced p53 in the cell line treated with TMPyP4. As the concentration increased, there 
was a second band that appeared due to increased expression. Unfortunately there was an 
error in loading the gel, and the band for cDNA with exon 2/3 primers treated with 50 
µM TMPyP4 did not load. Had this been properly executed, there is a possibility of 
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looking at dose dependent increase in expression. The results from this gel 
electrophoresis further validate the data obtained from RT-qPCR.  
 
 
 
 
 
 
 
 
Figure 11 gel electrophoresis performed on cDNA treated with TMPyP2 and TMPyP4 
and specific primers displaying increase in expression with TMPyP4  
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CONCLUSION 
 
In America, breast cancer is the second most common cancer among women, and 
an estimated 246,660 new cases will be diagnosed in 2016 (American Cancer Society, 
2016). While the 5-year survival rates for early stages of breast cancer is now over 90%, 
metastatic breast cancer still poses a huge threat with its 5-year survival rate of 26% 
(Susan G. Komen, 2015). The need for more therapeutic options is evident. The ability to 
modulate secondary DNA structures, thus regulating gene expression and disease 
pathology, has recently sparked interest in the pharmaceutical industry (Fujiwara, 2015). 
Because p53 is inactivated in over 50% of cancer cases, its reorganization and 
reactivation is an attractive target for drug design (Miller, 2015). In addition, the 
inactivation of p53 is known to cause more aggressive and therapeutically refractory 
breast cancer tumors and correcting p53 function has a large potential of clinical impact 
(Miller, 2005). An innovative approach to targeting inactivated p53 is the stabilization of 
these secondary DNA structures called G-quadruplexes to re-correct splicing events and 
facilitate functional protein. As implicated in this study, the stabilization of G-
quadruplexes within intron 3 leads to the correct alternative splicing of intron 2, thus 
creating a functional p53 capable of regulating the cell cycle. Our work focused on 
clarifying the particular G-quadruplexes formed in intron 3, stabilizing it with a small 
molecule, and confirming its role in pre-mRNA splicing events. Other future areas of 
research involve pharmacological and pharmacokinetic testing to identify and better 
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understand the relationship between selective small molecules and the stabilization of 
p53’s intron 3 G-quadruplex.  
Over 40% of the human genome is regulated by G-quadruplex structures; hence, 
their stabilization could have the potential to alter the treatment of many diseases,
including cancer (Fujiwara, 2015). G-quadruplexes have been found in DNA sequences 
in promoters, origins of replication, telomeres and centromeres in addition to mRNA in 
3’ UTR’s, introns and in ribosomal RNA. They play important roles in transcription, 
replication and genome integrity (Murat, 2014). The main function of p53 is cell cycle 
regulation through many different pathways. Without p53, DNA mutations can be 
propagated, thus facilitating the formation of cancers. If the inactivation of p53 could be 
corrected through the drug targeting of G-quadruplexes, there would be profound 
implications in the treatment of breast and many other cancers.  
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